Targets the retained glycosylated MUC16 fraction instead of shed CA-125, enabling more reliable ovarian cancer binding and tumor inhibition.
Sequential filtration with decreasing pore sizes isolates mucin from solution using a bubble column.
Peptide compounds bind tumor-associated Mucin-1 to differentiate malignant cells from healthy tissue, preventing autoimmune reactions.